IMPORTANCE: There is an immediate need to develop local intraoperative adjuvant treatment strategies to improve outcomes in patients with cancer who undergo head and neck surgery. OBJECTIVES: To determine the safety of photodynamic therapy with 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) in combination with surgery in patients with head and neck squamous cell carcinoma. DESIGN, SETTING, AND PARTICIPANTS: Nonrandomized, single-arm, single-site, phase 1 study at a comprehensive cancer center among 16 adult patients (median age, 65 years) with biopsy-proved primary or recurrent resectable head and neck squamous cell carcinoma. INTERVENTIONS: Intravenous injection of HPPH (4.0 mg/m2), followed by activation with 665-nm laser light in the surgical bed immediately after tumor resection. MAIN OUTCOMES AND MEASURES: Adverse events and highest laser light dose. RESULTS: Fifteen patients received the full course of treatment, and 1 patient received HPPH without intraoperative laser light because of an unrelated myocardial infarction. Disease sites included larynx (7 patients), oral cavity (6 patients), skin (1 patient), ear canal (1 patient), and oropharynx (1 patient, who received HPPH only). The most frequent adverse events related to photodynamic therapy were mild to moderate edema (9 patients) and pain (3 patients). One patient developed a grade 3 fistula after salvage laryngectomy, and another patient developed a grade 3 wound infection and mandibular fracture. Phototoxicity reactions included 1 moderate photophobia and 2 mild to moderate skin burns (2 due to operating room spotlights and 1 due to the pulse oximeter). The highest laser light dose was 75 J/cm2. CONCLUSIONS AND RELEVANCE: The adjuvant use of HPPH-photodynamic therapy and surgery for head and neck squamous cell carcinoma seems safe and deserves further study. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00470496.
IMPORTANCE: There is an immediate need to develop local intraoperative adjuvant treatment strategies to improve outcomes in patients with cancer who undergo head and neck surgery. OBJECTIVES: To determine the safety of photodynamic therapy with 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) in combination with surgery in patients with head and neck squamous cell carcinoma. DESIGN, SETTING, AND PARTICIPANTS: Nonrandomized, single-arm, single-site, phase 1 study at a comprehensive cancer center among 16 adult patients (median age, 65 years) with biopsy-proved primary or recurrent resectable head and neck squamous cell carcinoma. INTERVENTIONS: Intravenous injection of HPPH (4.0 mg/m2), followed by activation with 665-nm laser light in the surgical bed immediately after tumor resection. MAIN OUTCOMES AND MEASURES: Adverse events and highest laser light dose. RESULTS: Fifteen patients received the full course of treatment, and 1 patient received HPPH without intraoperative laser light because of an unrelated myocardial infarction. Disease sites included larynx (7 patients), oral cavity (6 patients), skin (1 patient), ear canal (1 patient), and oropharynx (1 patient, who received HPPH only). The most frequent adverse events related to photodynamic therapy were mild to moderate edema (9 patients) and pain (3 patients). One patient developed a grade 3 fistula after salvage laryngectomy, and another patient developed a grade 3 wound infection and mandibular fracture. Phototoxicity reactions included 1 moderate photophobia and 2 mild to moderate skin burns (2 due to operating room spotlights and 1 due to the pulse oximeter). The highest laser light dose was 75 J/cm2. CONCLUSIONS AND RELEVANCE: The adjuvant use of HPPH-photodynamic therapy and surgery for head and neck squamous cell carcinoma seems safe and deserves further study. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00470496.
Authors: Hector R Nava; Shyam S Allamaneni; Thomas J Dougherty; Michele T Cooper; Wei Tan; Gregory Wilding; Barbara W Henderson Journal: Lasers Surg Med Date: 2011-09 Impact factor: 4.025
Authors: Gregory M Loewen; Ravindra Pandey; David Bellnier; Barbara Henderson; Thomas Dougherty Journal: Lasers Surg Med Date: 2006-06 Impact factor: 4.025
Authors: Nestor R Rigual; Krishnakumar Thankappan; Michele Cooper; Maureen A Sullivan; Thomas Dougherty; Saurin R Popat; Thom R Loree; Merrill A Biel; Barbara Henderson Journal: Arch Otolaryngol Head Neck Surg Date: 2009-08
Authors: Richard W Nason; Abdulaziz Binahmed; Kumar A Pathak; Ahmed A Abdoh; George K B Sándor Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2009-01-25
Authors: Gal Shafirstein; Athar Battoo; Kassem Harris; Heinz Baumann; Sandra O Gollnick; Joerg Lindenmann; Chukwumere E Nwogu Journal: Ann Am Thorac Soc Date: 2016-02
Authors: Nestor Rigual; Gal Shafirstein; Michele T Cooper; Heinz Baumann; David A Bellnier; Ulas Sunar; Erin C Tracy; Daniel J Rohrbach; Gregory Wilding; Wei Tan; Maureen Sullivan; Mihai Merzianu; Barbara W Henderson Journal: Clin Cancer Res Date: 2013-10-02 Impact factor: 12.531
Authors: Gal Shafirstein; Nestor R Rigual; Hassan Arshad; Michele T Cooper; David A Bellnier; Gregory Wilding; Wei Tan; Mihai Merzianu; Barbara W Henderson Journal: Head Neck Date: 2015-06-29 Impact factor: 3.147